Saeland, Eirikur http://orcid.org/0000-0002-7060-1181
van der Fits, Leslie
Bolder, Renske http://orcid.org/0000-0001-7539-4524
Heemskerk-van der Meer, Marjolein
Drijver, Joke
van Polanen, Yolinda http://orcid.org/0000-0001-9016-9819
Vaneman, Cornelis
Tettero, Lisanne
Cox, Freek
Serroyen, Jan
Jorgensen, Matthew J. http://orcid.org/0000-0002-0977-6425
Langedijk, Johannes P. M. http://orcid.org/0000-0001-8768-0982
Schuitemaker, Hanneke http://orcid.org/0000-0001-8563-2266
Callendret, Benoit
Zahn, Roland C. http://orcid.org/0000-0003-2822-6231
Funding for this research was provided by:
Janssen Pharmaceuticals
U.S. Department of Health & Human Services | National Institutes of Health (P40-OD010965)
Article History
Received: 27 September 2022
Accepted: 27 February 2023
First Online: 23 March 2023
Competing interests
: All authors except M.J.J. are employees of Janssen Infectious Diseases & Vaccines, and may own stock or stock options in Johnson & Johnson, its parent company. M.J.J. has no competing interests to report.